EXTENT OF USE OF VALIDATED SELF-REPORTED COST DATA COLLECTION TOOLS IN TRIAL-BASED ECONOMIC EVALUATIONS FOR OSTEOARTHRITIS: A SYSTEMATIC REVIEW...
Author(s)
Moody Gayed, Specialist Diploma in Public Health (DPH).
Centre for Musculoskeletal Outcomes Research, University of Otago, Dunedin, New Zealand.
Centre for Musculoskeletal Outcomes Research, University of Otago, Dunedin, New Zealand.
OBJECTIVES: To investigate the extent of use of validated self-reported cost data collection tools in trial-based economic evaluations of non-pharmacological, non-surgical interventions for osteoarthritis, and to describe associations with study characteristics
METHODS: We searched English published trial-based economic evaluations in MEDLINE, EMBASE, PubMed, CINAHL, Econlit, HTA, DARE and NHS EED. Eligible studies were examined for both general study characteristics and characteristics of cost data collection tools. For evidence synthesis, we classified cost data collection tools into self-reported and non-self-reported tools and classified studies applying self-reported tools into validated and non-validated subgroups and compared differences accordingly
RESULTS: Our search yielded 4213 articles. After deduplication and title and abstract screening, 259 were screened for full text, and 51 studies were included. Self-reported cost data collection tools were used more frequently than non-self-reported methods across the included studies (n=40 and n=32, respectively). Among those using self-reported tools, validated tools were reported by 9 studies (22.5%), and non-validated tools by 31 studies (77.5%). The adoption of complex trial designs, societal and combined perspectives, and positive cost-effective conclusions was more frequently observed among trial-based economic evaluations using validated tools than among those in the non-validated group.
CONCLUSIONS: Our review demonstrates an underuse of validated self-reported cost data collection tools investigating non-pharmacological, non-surgical interventions in trial-based economic evaluations for osteoarthritis. The observed association between the use of non-validated cost tools, narrower analytical perspectives, and the use of simpler trial designs may reflect underlying limitations in methodological and research capacity. This evidence suggests considering validation of self-reported cost data measures as an integral part of study quality assessment in health economics guidelines.
METHODS: We searched English published trial-based economic evaluations in MEDLINE, EMBASE, PubMed, CINAHL, Econlit, HTA, DARE and NHS EED. Eligible studies were examined for both general study characteristics and characteristics of cost data collection tools. For evidence synthesis, we classified cost data collection tools into self-reported and non-self-reported tools and classified studies applying self-reported tools into validated and non-validated subgroups and compared differences accordingly
RESULTS: Our search yielded 4213 articles. After deduplication and title and abstract screening, 259 were screened for full text, and 51 studies were included. Self-reported cost data collection tools were used more frequently than non-self-reported methods across the included studies (n=40 and n=32, respectively). Among those using self-reported tools, validated tools were reported by 9 studies (22.5%), and non-validated tools by 31 studies (77.5%). The adoption of complex trial designs, societal and combined perspectives, and positive cost-effective conclusions was more frequently observed among trial-based economic evaluations using validated tools than among those in the non-validated group.
CONCLUSIONS: Our review demonstrates an underuse of validated self-reported cost data collection tools investigating non-pharmacological, non-surgical interventions in trial-based economic evaluations for osteoarthritis. The observed association between the use of non-validated cost tools, narrower analytical perspectives, and the use of simpler trial designs may reflect underlying limitations in methodological and research capacity. This evidence suggests considering validation of self-reported cost data measures as an integral part of study quality assessment in health economics guidelines.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EE89
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Trial-Based Economic Evaluation, Value of Information
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), STA: Alternative Medicine